Leading biotechnology company Panacea Biotec is planning to introduce its indigenously developed albumin bound Paclitaxel particles formulation – PacliALL. It will be launched on February 12, during the Indian Cancer Congress 2011 at Bhubaneswar.
PacliALL offers the advantage of improved safety over conventional formulations of Paclitaxel and is meant to be used as a chemotherapeutic agent for the treatment of breast cancer. PacliALL would be made available at a price point which is approximately 50 per cent lower than competitive products in the domestic and global markets, according to a release from the company. PacliALL has been developed by Panacea Biotec’s state of the art Global Research and Development (GRAND) Centre, Navi Mumbai.
Commenting on the same, Dr Rajesh Jain, jt managing director, Panacea Biotec Limited said, “the objective of Panacea Biotec is to take ideas from grey cells to the market in a proactive manner. PacliAll uses one of world’s most advanced particle size optimization technology to reduce serious adverse effects like severe anaphylaxis and sensory neuropathy associated with conventional Paclitaxel formulations in addition to offering several patient convenience aspects like shorter infusion time and elimination of need of premedication.’’
Worldwide, female breast cancer comprises 10.4 per cent of all cancer incidences among women, making it the most common type of non-skin cancer in women and the fifth most common cause of cancer death. According to WHO, female breast cancer is one of the major challenges where almost 1 out of 8 women is going to have this dreaded disease by 2020 across the Globe. In India around 80000+ patients are diagnosed with breast cancer every year.
The product portfolio of the Panacea includes highly innovative prescription products in important therapeutic areas such as pain management, diabetes management, renal-disease management, anti-osteoporosis, anti-tubercular, gastro-intestinal care products and vaccines.